Azzad Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Azzad Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,035	Closed	-$868K	–	322
2022 Q3	$868K	Sell	7,035 -1	-0%	-$89	0.09%	292
2022 Q2	$868K	Buy	+7,036	New	+$560K	0.09%	291
2020 Q3	–	Sell	-7,030	Closed	-$867K	–	292
2020 Q2	$867K	Sell	7,030 -2	-0%	-$199	0.2%	166
2020 Q1	$594K	Sell	7,032 -7,030	-50%	-$606K	0.17%	194
2019 Q4	$1.46M	Hold	14,062	–	–	0.17%	190
2019 Q3	$1.34M	Buy	14,062 +7,036	+100%	+$542K	0.17%	198
2019 Q2	$602K	Buy	7,026 +481	+7%	+$41.1K	0.17%	212
2019 Q1	$581K	Buy	6,545 +338	+5%	+$31.3K	0.17%	204
2018 Q4	$529K	Hold	6,207	–	–	0.18%	204
2018 Q3	$602K	Hold	6,207	–	–	0.16%	216
2018 Q2	$585K	Buy	6,207 +357	+6%	+$31.3K	0.17%	210
2018 Q1	$474K	Hold	5,850	–	–	0.14%	230
2017 Q4	$522K	Hold	5,850	–	–	0.16%	194
2017 Q3	$544K	Hold	5,850	–	–	0.18%	189
2017 Q2	$531K	Sell	5,850 -2,500	-30%	-$227K	0.19%	184
2017 Q1	$733K	Hold	8,350	–	–	0.28%	148
2016 Q4	$692K	Hold	8,350	–	–	0.29%	136
2016 Q3	$773K	Hold	8,350	–	–	0.32%	122
2016 Q2	$650K	Hold	8,350	–	–	0.28%	137
2016 Q1	$689K	Hold	8,350	–	–	0.3%	129
2015 Q4	$875K	Hold	8,350	–	–	0.42%	97
2015 Q3	$879K	Sell	8,350 -1,220	-13%	-$163K	0.46%	80
2015 Q2	$1.31M	Hold	9,570	–	–	0.66%	31
2015 Q1	$1.19M	Hold	9,570	–	–	0.57%	41
2014 Q4	$865K	Buy	9,570 +1,469	+18%	+$122K	0.46%	75
2014 Q3	$585K	Buy	8,101 +1,412	+21%	+$92.8K	0.34%	119
2014 Q2	$416K	Sell	6,689 -3,631	-35%	-$219K	0.25%	158
2014 Q1	$684K	Buy	10,320 +2,265	+28%	+$167K	0.45%	82
2013 Q4	$567K	Hold	8,055	–	–	0.41%	97
2013 Q3	$581K	Buy	+8,055	New	+$535K	0.48%	73

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Azzad Asset Management's BMRN Position: Q4 2022 in Review

Azzad Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2022, closing a stake of 7,035 shares — an estimated $868K sold.

Azzad Asset Management first reported a position in BMRN in Q3 2013 and held it in 30 quarters. The position peaked at $1.46M in Q4 2019. 580 funds tracked by Wall St. Rank hold BMRN as of Q4 2022.

Azzad Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Azzad Asset Management sold 7,035 BioMarin Pharmaceuticals shares in Q4 2022, an estimated $868K.
Azzad Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 30 quarters.
Azzad Asset Management's BioMarin Pharmaceuticals position peaked at $1.46M in Q4 2019.
580 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2022.

Based on Azzad Asset Management's 13F filing for Q4 2022, filed 1 Apr 2024.